Great honour today to be the keynote speaker on Brexit at BioTrinity.
There was a fascinating discussion today at Biotrinity on what Brexit means for the biotech world. It was good to hear people make clear they don’t see the change in relationship as all negative, and confidence in the UK’s opportunities remains high.
What business wants most is clarity on our future, the ongoing self inflicted debate is what harms us. Participation here in Europe’s leading Biopartnering and Investment conference shows the importance of the UK in this space. Fund raising and talent opportunities for life science companies, academics, investors, and major pharmaceutical players in the UK do not seem unduly dented by the B word, and that is my key take away.